论文部分内容阅读
目的:探讨CA125作为上皮性卵巢癌诊断标志物的临床价值。方法:随机选择健康女性50例、良性卵巢肿瘤患者50例、上皮性卵巢癌患者52例作为研究对象,检测各组人群血清CA125蛋白表达水平。结果:3组研究对象的年龄没有统计学差异(F=22.14,P=0.134);上皮性卵巢癌患者的血清CA125水平明显高于健康女性与良性卵巢肿瘤患者(P值均<0.01),卵巢良性疾病组CA125与正常对照组比较无统计学差异(P=0.562);CA125在卵巢癌晚期(Ⅲ期+Ⅳ期)高于卵巢癌早期(Ⅰ期+Ⅱ期),随着病情进展,呈上升趋势;非粘液性卵巢癌患者血清CA125明显升高,粘液性卵巢癌患者血清CA125升高不明显,2者血清CA125水平比较具有统计学差异(P<0.01);某些良性卵巢肿瘤CA125水平也会高于正常,但一般强度不高。结论:作为上皮性卵巢癌肿瘤标记物,CA125有较好的诊断价值。
Objective: To investigate the clinical value of CA125 as a diagnostic marker of epithelial ovarian cancer. Methods: 50 healthy women, 50 benign ovarian cancer patients and 52 epithelial ovarian cancer patients were randomly selected as the research object to detect the serum CA125 protein expression in each group. Results: There was no significant difference in the age of the three groups (F = 22.14, P = 0.134). The serum CA125 level in patients with epithelial ovarian cancer was significantly higher than that in healthy women and benign ovarian tumors (P <0.01) There was no significant difference between benign disease group CA125 and normal control group (P = 0.562); CA125 was higher in advanced stage of ovarian cancer (stage Ⅲ + Ⅳ) than in early stage of ovarian cancer (stage Ⅰ + Ⅱ) (P <0.01); CA125 levels in some benign ovarian tumors were significantly higher than those in non-mucinous ovarian cancer patients (P <0.01) Will be higher than normal, but the general strength is not high. Conclusion: As a tumor marker of epithelial ovarian cancer, CA125 has good diagnostic value.